Wide Ranks

GRI

GRI Bio, Inc.

0.7600

Top Statistics
Market Cap 6 M Forward PE -0.2890 Revenue Growth 0.00 %
Current Ratio 3.11 Trailing PE 0.0098 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.4720 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 6 M Total Cash Per Share 2.17 Total Debt 141000
Total Debt To Equity 2.99 Current Ratio 3.11 Book Value Per Share 5.21
All Measures
Short Ratio 10.00 % Message Board Id finmb_136941170 Shares Short Prior Month 169124
Return On Equity -1.89 City LA Jolla Uuid 2a4b9e2e-4254-393c-ba83-44e16bef237a
Previous Close 0.7330 First Trade Date Epoch Utc 1 B Book Value 5.21
Total Debt 141000 Volume 136156 Price To Book 0.1458
Last Split Date 1 B Fifty Two Week Low 0.3020 Total Cash Per Share 2.17
Shares Short Previous Month Date 1 B Target Median Price 12.00 Max Age 86400
Sand P52 Week Change 0.3133 Target Mean Price 12.00 Net Income To Common -8278000
Short Percent Of Float 0.2511 Implied Shares Outstanding 8 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 368080 Average Volume10days 368080
Total Cash 6 M Next Fiscal Year End 1 B Held Percent Insiders 0.0035
Trailing PE 0.0098 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 0.7330 Target Low Price 12.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 0.6512 Open 0.7160 Free Cashflow -3866375
State CA Dividend Yield 0.00 % Return On Assets -0.8253
Time Zone Short Name EST Trailing Eps 77.53 Day Low 0.7160
Address1 2223 Avenida de la Playa Shares Outstanding 8 M Price Hint 4
Target High Price 12.00 Website https://www.gribio.com 52 Week Change -0.9863
Average Volume 4 M Forward Eps -2.63 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 286.70 % Last Split Factor 1:13
Regular Market Day High 0.7700 Is_sp_500 False Profit Margins 0.00 %
Debt To Equity 2.99 Fifty Two Week High 106.29 Day High 0.7700
Shares Short 924631 Regular Market Open 0.7160 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.2506
Operating Cashflow -11215000 Currency USD Time Zone Full Name America/New_York
Market Cap 6 M Is_nasdaq_100 False Zip 92037
Quote Type EQUITY Industry Biotechnology Long Name GRI Bio, Inc.
Regular Market Day Low 0.7160 Held Percent Institutions 0.0471 Current Price 0.7600
Address2 Suite 208 Enterprise To Ebitda 0.4720 Financial Currency USD
Current Ratio 3.11 Industry Disp Biotechnology Number Of Analyst Opinions 1
Country United States Float Shares 2 M Two Hundred Day Average 3.69
Enterprise Value -3951517 Forward PE -0.2890 Regular Market Volume 136156
Ebitda -8363000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States.

Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase II clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.

The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 for the treatment of primary sclerosing cholangitis, and GRI-0729, which are in pre-clinical development.

GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.